On Oct. 19, 2020, ICON announced that it had been re-selected by the Biomedical Advanced Research and Development Authority (BARDA) to continue being part of its exclusive Medical Countermeasures Clinical Studies Network (CSN).

ICON continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development. The company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies.